iTeos Therapeutics (ITOS) Short Interest Ratio & Short Volume $9.97 +0.02 (+0.20%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock iTeos Therapeutics Short Interest DataiTeos Therapeutics (ITOS) has a short interest of 2.70 million shares, representing 8.06% of the float (the number of shares available for trading by the public). This marks a 6.72% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.1, indicating that it would take 2.1 days of the average trading volume of 687,156 shares to cover all short positions.Current Short Interest2,700,000 sharesPrevious Short Interest2,530,000 sharesChange Vs. Previous Month+6.72%Dollar Volume Sold Short$27.46 millionShort Interest Ratio2.1 Days to CoverLast Record DateJune 15, 2025Outstanding Shares38,270,000 sharesShort Percent of Float8.06%Today's Trading Volume717,444 sharesAverage Trading Volume687,156 sharesToday's Volume Vs. Average104% Short Selling iTeos Therapeutics? Sign up to receive the latest short interest report for iTeos Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartITOS Short Interest Over TimeITOS Days to Cover Over TimeITOS Percentage of Float Shorted Over Time iTeos Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20252,700,000 shares $27.46 million +6.7%8.1%2.1 $10.17 5/31/20252,530,000 shares $25.25 million -7.7%7.9%2.1 $9.98 5/15/20252,740,000 shares $21.84 million +8.3%8.6%3.2 $7.97 4/30/20252,530,000 shares $18.34 million +25.3%7.6%6.3 $7.25 4/15/20252,020,000 shares $11.98 million +10.4%6.1%5.6 $5.93 3/31/20251,830,000 shares $10.93 million +33.6%5.5%5.8 $5.97 3/15/20251,370,000 shares $10.03 million +7.0%4.2%3.8 $7.32 2/28/20251,280,000 shares $9.29 million -19.0%3.9%3.5 $7.26 2/15/20251,580,000 shares $11.69 million +12.1%5.1%4.2 $7.40 1/31/20251,410,000 shares $10.63 million +5.2%4.6%3.4 $7.54 Get the Latest News and Ratings for ITOS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20251,340,000 shares $10.41 million -10.7%4.4%2.7 $7.77 12/31/20241,500,000 shares $11.52 million -21.1%4.9%2.7 $7.68 12/15/20241,900,000 shares $14.59 million -3.1%6.2%3.2 $7.68 11/30/20241,960,000 shares $16.76 million -11.3%6.4%2.8 $8.55 11/15/20242,210,000 shares $18.19 million -29.2%7.2%3.1 $8.23 10/31/20243,120,000 shares $26.36 million -18.3%11.1%4.7 $8.45 10/15/20243,820,000 shares $35.98 million -20.8%13.6%6.3 $9.42 9/30/20244,820,000 shares $49.21 million +92.0%17.2%9.3 $10.21 9/15/20242,510,000 shares $41.92 million -3.8%8.9%5 $16.70 8/31/20242,610,000 shares $43.98 million +4.4%9.3%7.3 $16.85 8/15/20242,500,000 shares $38.53 million -0.8%8.9%7.4 $15.41 7/31/20242,520,000 shares $44.33 million -4.2%9.1%5.6 $17.59 7/15/20242,630,000 shares $43.63 million +1.2%9.5%6 $16.59 6/30/20242,600,000 shares $38.58 million +16.1%9.4%6 $14.84 6/15/20242,240,000 shares $36.36 million +8.2%8.1%5.1 $16.23 5/31/20242,070,000 shares $34.65 million -4.2%7.5%5.2 $16.74 5/15/20242,160,000 shares $38.79 million +4.4%7.8%5.2 $17.96 4/30/20242,070,000 shares $22.23 million -2.4%7.2%7.2 $10.74 4/15/20242,120,000 shares $24.93 million +3.4%7.4%7.7 $11.76 3/31/20242,050,000 shares $27.96 million +2.0%7.2%7.2 $13.64 3/15/20242,010,000 shares $21.73 million +11.7%7.1%7.8 $10.81 2/29/20241,800,000 shares $19.28 million +5.9%6.3%6 $10.71 2/15/20241,700,000 shares $17.12 million -1.7%6.0%5.5 $10.07 1/31/20241,730,000 shares $17.21 million +16.1%6.1%5.7 $9.95 1/15/20241,490,000 shares $16.88 million -6.9%5.2%4.5 $11.33 12/31/20231,600,000 shares $17.52 million -21.2%5.6%3.4 $10.95 12/15/20232,030,000 shares $22.03 million +17.3%7.1%4.3 $10.85 11/30/20231,730,000 shares $16.19 million +8.8%6.1%4 $9.36 11/15/20231,590,000 shares $16.01 million -9.1%5.6%3.7 $10.07 10/31/20231,750,000 shares $17.61 million -24.6%6.0%3.1 $10.06Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 10/15/20232,320,000 shares $20.97 million +28.2%7.9%4.3 $9.04 9/30/20231,810,000 shares $19.82 million +7.7%6.2%4.7 $10.95 9/15/20231,680,000 shares $20.70 million +3.7%5.7%4.4 $12.32 8/31/20231,620,000 shares $19.55 million +5.9%5.5%3.8 $12.07 8/15/20231,530,000 shares $18.21 million +8.5%5.3%3.5 $11.90 7/31/20231,410,000 shares $19.82 million -0.7%4.9%5.1 $14.06 7/15/20231,420,000 shares $19.51 million -6.0%4.9%5 $13.74 6/30/20231,510,000 shares $19.99 million -14.2%5.2%5.1 $13.24 6/15/20231,760,000 shares $24.99 million -7.4%6.1%6.1 $14.20 5/31/20231,900,000 shares $30.93 million +6.7%6.6%7.1 $16.28 5/15/20231,780,000 shares $26.52 million +6.6%6.1%7.3 $14.90 4/30/20231,670,000 shares $22.95 million -2.9%5.8%6.9 $13.74 4/15/20231,720,000 shares $23.50 million +1.8%5.9%6.8 $13.66 3/31/20231,690,000 shares $23.00 million +11.2%5.8%6.1 $13.61 3/15/20231,520,000 shares $23.91 million +2.0%5.3%5.2 $15.73 2/28/20231,490,000 shares $26.39 million +0.7%5.2%4.7 $17.71 2/15/20231,480,000 shares $27.44 million +0.7%5.1%4.6 $18.54 1/31/20231,470,000 shares $30.72 million +0.7%5.1%4.4 $20.90 1/15/20231,460,000 shares $27.84 million +5.0%5.1%4.4 $19.07 12/30/20221,390,000 shares $27.15 million -22.8%4.8%4.3 $19.53 12/15/20221,800,000 shares $38.65 million +9.8%6.2%5.9 $21.47 11/30/20221,640,000 shares $33.05 million -12.3%5.7%5.4 $20.15 11/15/20221,870,000 shares $38.67 million -7.4%6.5%6.1 $20.68 10/31/20222,020,000 shares $39.35 million +3.1%7.0%6.3 $19.48 10/15/20221,960,000 shares $35.32 million -27.4%6.8%5.9 $18.02 9/30/20222,700,000 shares $51.44 million +0.4%9.4%7.5 $19.05 9/15/20222,690,000 shares $54.61 million -0.4%9.3%7.1 $20.30 8/31/20222,700,000 shares $59.89 million -5.6%9.4%6.8 $22.18 8/15/20222,860,000 shares $72.64 million -1.7%9.9%6.8 $25.40 7/31/20222,910,000 shares $71.18 million +0.3%10.1%6.1 $24.46 7/15/20222,900,000 shares $71.05 million +4.3%10.1%5.8 $24.50 6/30/20222,780,000 shares $57.27 million +28.7%9.6%5.8 $20.60 6/15/20222,160,000 shares $39.68 million +9.6%7.5%4.4 $18.37 5/31/20221,970,000 shares $34.48 million +13.2%6.8%4.2 $17.50 5/15/20221,740,000 shares $32.33 million -17.9%6.0%4 $18.58 4/30/20222,120,000 shares $56.58 million +35.0%8.1%5.5 $26.69 4/15/20221,570,000 shares $51.28 million +9.8%6.0%4.1 $32.66 3/31/20221,430,000 shares $46.02 million +61.3%N/A0 $32.18 3/15/2022886,300 shares $31.84 million +0.0%3.5%1.7 $35.93 2/28/2022886,000 shares $32.01 million -4.0%3.5%1.8 $36.13 2/15/2022922,400 shares $33.27 million -30.1%3.9%1.8 $36.07 1/31/20221,320,000 shares $48.34 million -11.4%5.8%2.6 $36.62 1/15/20221,490,000 shares $59.09 million +108.5%N/A3.1 $39.66 12/31/2021714,800 shares $33.28 million +12.8%2.6%1.6 $46.56 12/15/2021633,700 shares $23.64 million +37.8%2.4%2.6 $37.31 11/30/2021460,000 shares $16.24 million -27.8%1.7%2.3 $35.30 11/15/2021636,900 shares $19.36 million -21.3%2.4%3.5 $30.40 10/29/2021809,500 shares $21.65 million +3.3%2.8%5.1 $26.75 10/15/2021784,000 shares $21.92 million -0.7%2.8%4.7 $27.96 9/30/2021789,300 shares $21.31 million +12.0%2.8%4.3 $27.00Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 9/15/2021704,600 shares $19.79 million -9.6%2.3%2.6 $28.09 8/31/2021779,500 shares $22.10 million -20.4%2.6%1.9 $28.35 8/13/2021979,000 shares $24.12 million -5.9%3.3%2 $24.64 7/30/20211,040,000 shares $24.99 million +11.2%3.5%2.2 $24.03 7/15/2021935,300 shares $22.58 million +11.1%3.2%2 $24.14 6/30/2021841,900 shares $21.59 million -49.9%2.9%1.8 $25.65 6/15/20211,680,000 shares $44.35 million -5.1%5.7%3.9 $26.40 5/28/20211,770,000 shares $36.36 million -8.3%6.0%5.9 $20.54 5/14/20211,930,000 shares $43.15 million +11.6%6.5%7.2 $22.36 4/30/20211,730,000 shares $41.36 million +11.6%5.9%7.1 $23.91 4/15/20211,550,000 shares $37.18 million +17.4%5.3%5.2 $23.99 3/31/20211,320,000 shares $42.73 million +128.4%4.5%4.7 $32.37 3/15/2021578,000 shares $22.62 million +24.4%2.0%2.1 $39.14 2/26/2021464,700 shares $19.42 million -5.9%1.6%2.1 $41.79 2/12/2021493,600 shares $17.92 million -13.8%1.7%2.4 $36.31 1/29/2021572,300 shares $18.40 million +0.4%1.9%2.9 $32.15 1/15/2021569,800 shares $18.93 million No Change1.9%3.5 $33.22 ITOS Short Interest - Frequently Asked Questions What is iTeos Therapeutics' current short interest? Short interest is the volume of iTeos Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 2,700,000 shares of ITOS short. 8.06% of iTeos Therapeutics' shares are currently sold short. Learn More on iTeos Therapeutics' current short interest. What is a good short interest ratio for iTeos Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ITOS shares currently have a short interest ratio of 2.0. Learn More on iTeos Therapeutics's short interest ratio. Which institutional investors are shorting iTeos Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of iTeos Therapeutics: Caption Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for iTeos Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.06% of iTeos Therapeutics' floating shares are currently sold short. Is iTeos Therapeutics' short interest increasing or decreasing? iTeos Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,700,000 shares, an increase of 6.7% from the previous total of 2,530,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does iTeos Therapeutics' short interest compare to its competitors? 8.06% of iTeos Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to iTeos Therapeutics: Edgewise Therapeutics, Inc. (16.25%), Schrodinger, Inc. (15.63%), Biohaven Ltd. (12.68%), 89BIO (9.84%), ANI Pharmaceuticals, Inc. (10.44%), Janux Therapeutics, Inc. (21.42%), Evotec AG (0.23%), Mesoblast Limited (2.59%), Vera Therapeutics, Inc. (20.84%), Ocular Therapeutix, Inc. (9.27%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short iTeos Therapeutics stock? Short selling ITOS is an investing strategy that aims to generate trading profit from iTeos Therapeutics as its price is falling. ITOS shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against iTeos Therapeutics? A short squeeze for iTeos Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ITOS, which in turn drives the price of the stock up even further. How often is iTeos Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ITOS, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Edgewise Therapeutics Short Interest Data Schrodinger Short Interest Data Biohaven Short Interest Data 89BIO Short Interest Data ANI Pharmaceuticals Short Interest Data Janux Therapeutics Short Interest Data Evotec Short Interest Data Mesoblast Short Interest Data Vera Therapeutics Short Interest Data Ocular Therapeutix Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ITOS) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts